COSMO Pharmaceuticals SA (COPN)

Currency in CHF
62.80
-0.80(-1.26%)
Closed·

COPN Financial Summary

Key Ratios

P/E Ratio18.32
Price/Book2.33
Debt / Equity0.58%
Return on Equity12.34%
Dividend Yield3.06%
EBITDA160.47M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of EUR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.68%
Dividend Yield
3.06%
Industry Median 2.31%
Annualised payout
1.92
Paid annually
5-Years Growth
-
Growth Streak

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 98.66
(+57.10% Upside)

Earnings

Latest Release
Jul 23, 2025
EPS / Forecast
-0.13 / 1.30
Revenue / Forecast
51.72M / --
EPS Revisions
Last 90 days

FAQ

What were COSMO Pharma's earnings for the latest quarter?

The COSMO Pharma EPS (TTM) is 3.68. COSMO Pharma reported sales of 51.72, net income of -2.01, and EPS of -0.13 for the latest quarter.

What was COSMO Pharma's net income for the latest quarter?

COSMO Pharma's net income for the latest quarter was -2.01.

How did COSMO Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 130.55 in the previous quarter to 51.72 in the latest quarter, and net income moved from 57.25 to -2.01 compared to the previous quarter.

What is COSMO Pharma's net profit margin on a TTM basis?

COSMO Pharma's trailing twelve months (TTM) net profit margin is 49.94%.

How does COSMO Pharma's debt to equity ratio compare to industry standards?

COSMO Pharma's total debt-to-equity ratio is 0.58%.

What is COSMO Pharma's return on investment on a TTM basis?

COSMO Pharma's trailing twelve months (TTM) return on investment (ROI) is 12.34%.

Did COSMO Pharma gain or lose cash last quarter?

In the latest quarter, COSMO Pharma's net change in cash was 6.45 million.

What were COSMO Pharma's total assets and liabilities in the latest quarter?

As of the latest quarter, COSMO Pharma reported total assets of 610.33 million and total liabilities of 48.72 million.

How has COSMO Pharma's total revenue grown this year?

COSMO Pharma's total revenue was 130.55 in the previous quarter and 51.72 in the latest quarter.

What is COSMO Pharma's gross margin on a TTM basis?

COSMO Pharma's trailing twelve months (TTM) gross margin is 73.79%.

What was COSMO Pharma's revenue per share for the latest quarter?

COSMO Pharma's revenue per share for the latest quarter was 54.95.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.